| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Antineoplastic Agents | 47 | 2023 | 13691 | 1.190 |
Why?
|
| Maximum Tolerated Dose | 31 | 2020 | 892 | 1.020 |
Why?
|
| Camptothecin | 12 | 2012 | 576 | 0.880 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 40 | 2023 | 11524 | 0.860 |
Why?
|
| Chromatography, High Pressure Liquid | 15 | 2009 | 1574 | 0.820 |
Why?
|
| Isoquinolines | 10 | 2005 | 364 | 0.730 |
Why?
|
| Brain Neoplasms | 25 | 2023 | 8856 | 0.690 |
Why?
|
| Asparaginase | 7 | 2021 | 236 | 0.640 |
Why?
|
| Glioma | 17 | 2020 | 3401 | 0.620 |
Why?
|
| Paclitaxel | 14 | 2020 | 1705 | 0.590 |
Why?
|
| Receptor, Platelet-Derived Growth Factor beta | 1 | 2017 | 188 | 0.550 |
Why?
|
| Quinazolines | 5 | 2017 | 1356 | 0.540 |
Why?
|
| Glioblastoma | 8 | 2023 | 3480 | 0.530 |
Why?
|
| Dioxoles | 6 | 2005 | 104 | 0.480 |
Why?
|
| Antineoplastic Agents, Phytogenic | 6 | 2020 | 623 | 0.480 |
Why?
|
| Infusions, Intravenous | 21 | 2020 | 2274 | 0.440 |
Why?
|
| Isoflavones | 3 | 2007 | 139 | 0.420 |
Why?
|
| Benzamides | 6 | 2020 | 1383 | 0.410 |
Why?
|
| Neoplasm Recurrence, Local | 17 | 2017 | 9239 | 0.400 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 6 | 2021 | 1520 | 0.400 |
Why?
|
| Drug Administration Schedule | 23 | 2020 | 4931 | 0.400 |
Why?
|
| Topoisomerase I Inhibitors | 2 | 2020 | 65 | 0.390 |
Why?
|
| Prodrugs | 4 | 2020 | 263 | 0.370 |
Why?
|
| Thionucleotides | 1 | 2009 | 107 | 0.350 |
Why?
|
| Procarbazine | 2 | 2006 | 181 | 0.350 |
Why?
|
| Carmustine | 2 | 2001 | 137 | 0.340 |
Why?
|
| Proto-Oncogene Proteins c-raf | 1 | 2009 | 203 | 0.330 |
Why?
|
| Fallopian Tube Neoplasms | 3 | 2020 | 324 | 0.330 |
Why?
|
| Piperazines | 2 | 2017 | 2487 | 0.320 |
Why?
|
| Blood-Brain Barrier | 5 | 2020 | 1018 | 0.320 |
Why?
|
| Carboplatin | 7 | 2019 | 801 | 0.310 |
Why?
|
| Antineoplastic Agents, Alkylating | 6 | 2015 | 627 | 0.310 |
Why?
|
| Leydig Cells | 1 | 2007 | 56 | 0.300 |
Why?
|
| Phytoestrogens | 1 | 2007 | 61 | 0.300 |
Why?
|
| Ovarian Neoplasms | 9 | 2021 | 4839 | 0.290 |
Why?
|
| Neoplasms | 20 | 2020 | 21675 | 0.290 |
Why?
|
| Farnesyltranstransferase | 2 | 2005 | 76 | 0.290 |
Why?
|
| Administration, Oral | 10 | 2017 | 3912 | 0.270 |
Why?
|
| Fluorouracil | 5 | 2011 | 1619 | 0.270 |
Why?
|
| Polyethylene Glycols | 4 | 2021 | 1181 | 0.260 |
Why?
|
| Hydrazines | 1 | 2007 | 225 | 0.260 |
Why?
|
| Antibiotics, Antineoplastic | 3 | 2001 | 690 | 0.250 |
Why?
|
| Tissue Distribution | 9 | 2017 | 2327 | 0.250 |
Why?
|
| Dose-Response Relationship, Drug | 23 | 2021 | 10940 | 0.250 |
Why?
|
| Enzyme Inhibitors | 6 | 2012 | 3794 | 0.250 |
Why?
|
| Peritoneal Neoplasms | 3 | 2020 | 665 | 0.250 |
Why?
|
| Dihydrouracil Dehydrogenase (NADP) | 1 | 2004 | 14 | 0.240 |
Why?
|
| Azepines | 2 | 2016 | 334 | 0.240 |
Why?
|
| Benzazepines | 2 | 2016 | 326 | 0.240 |
Why?
|
| Thymidylate Synthase | 1 | 2004 | 75 | 0.240 |
Why?
|
| Purine Nucleosides | 1 | 2003 | 30 | 0.240 |
Why?
|
| Testis | 1 | 2007 | 795 | 0.230 |
Why?
|
| Dacarbazine | 3 | 2017 | 566 | 0.230 |
Why?
|
| Anticonvulsants | 7 | 2012 | 1910 | 0.230 |
Why?
|
| Naphthalenes | 2 | 1995 | 194 | 0.230 |
Why?
|
| Pyrimidines | 5 | 2017 | 2945 | 0.230 |
Why?
|
| Drug Synergism | 2 | 2007 | 1794 | 0.220 |
Why?
|
| Sonication | 2 | 2020 | 83 | 0.220 |
Why?
|
| Pharmaceutical Preparations | 2 | 2022 | 1070 | 0.220 |
Why?
|
| Gas Chromatography-Mass Spectrometry | 5 | 2008 | 361 | 0.220 |
Why?
|
| Benzodiazepines | 2 | 2005 | 1101 | 0.210 |
Why?
|
| Dogs | 9 | 2016 | 3911 | 0.210 |
Why?
|
| Area Under Curve | 12 | 2008 | 1654 | 0.210 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 7 | 2012 | 5230 | 0.210 |
Why?
|
| Hyperglycemic Hyperosmolar Nonketotic Coma | 1 | 2022 | 24 | 0.210 |
Why?
|
| Imidazoles | 2 | 2005 | 1206 | 0.210 |
Why?
|
| Middle Aged | 73 | 2021 | 213241 | 0.210 |
Why?
|
| Erwinia | 2 | 2013 | 23 | 0.210 |
Why?
|
| Metabolic Clearance Rate | 7 | 2005 | 380 | 0.210 |
Why?
|
| Pyrazines | 5 | 2010 | 1230 | 0.210 |
Why?
|
| Aged | 63 | 2021 | 163178 | 0.200 |
Why?
|
| Sirolimus | 3 | 2013 | 1565 | 0.200 |
Why?
|
| Peptide Chain Initiation, Translational | 2 | 2012 | 103 | 0.200 |
Why?
|
| Male | 89 | 2021 | 349776 | 0.200 |
Why?
|
| Adult | 65 | 2021 | 213889 | 0.190 |
Why?
|
| Isoindoles | 1 | 2020 | 41 | 0.190 |
Why?
|
| Acidosis, Lactic | 1 | 2022 | 142 | 0.190 |
Why?
|
| Pyrimethamine | 1 | 2021 | 96 | 0.190 |
Why?
|
| Isoleucine | 1 | 2000 | 112 | 0.190 |
Why?
|
| Zinc Fingers | 2 | 2000 | 583 | 0.190 |
Why?
|
| Female | 87 | 2022 | 380020 | 0.180 |
Why?
|
| Sulfonamides | 4 | 2016 | 1938 | 0.180 |
Why?
|
| Lymphoma | 3 | 2022 | 1875 | 0.180 |
Why?
|
| Hydroxamic Acids | 4 | 2017 | 494 | 0.180 |
Why?
|
| Androgens | 1 | 2007 | 1247 | 0.180 |
Why?
|
| Spectrophotometry, Ultraviolet | 5 | 2000 | 220 | 0.180 |
Why?
|
| Hydroxychloroquine | 2 | 2014 | 412 | 0.170 |
Why?
|
| Brefeldin A | 2 | 1998 | 72 | 0.170 |
Why?
|
| Disease-Free Survival | 8 | 2017 | 6895 | 0.160 |
Why?
|
| Humans | 111 | 2023 | 743811 | 0.150 |
Why?
|
| Calcium Channels, T-Type | 1 | 2017 | 34 | 0.150 |
Why?
|
| Sarcoma | 3 | 2005 | 1898 | 0.150 |
Why?
|
| Piperidines | 3 | 2020 | 1601 | 0.150 |
Why?
|
| Boronic Acids | 4 | 2010 | 965 | 0.140 |
Why?
|
| STAT3 Transcription Factor | 1 | 2021 | 873 | 0.140 |
Why?
|
| Dexamethasone | 4 | 2017 | 1950 | 0.140 |
Why?
|
| Proto-Oncogene Proteins c-met | 1 | 2020 | 579 | 0.140 |
Why?
|
| Leukemia, Lymphocytic, Chronic, B-Cell | 2 | 2021 | 1596 | 0.140 |
Why?
|
| Pyrazoles | 3 | 2020 | 1970 | 0.140 |
Why?
|
| Carcinoma, Transitional Cell | 3 | 2016 | 808 | 0.140 |
Why?
|
| Receptor, erbB-3 | 1 | 2016 | 142 | 0.130 |
Why?
|
| Treatment Outcome | 27 | 2017 | 63042 | 0.130 |
Why?
|
| Monoterpenes | 1 | 1995 | 20 | 0.130 |
Why?
|
| Lung Neoplasms | 7 | 2012 | 13112 | 0.130 |
Why?
|
| Phenylurea Compounds | 3 | 2013 | 528 | 0.130 |
Why?
|
| Spectrometry, Mass, Electrospray Ionization | 3 | 2006 | 277 | 0.130 |
Why?
|
| Terpenes | 1 | 1995 | 97 | 0.130 |
Why?
|
| Quinones | 1 | 1995 | 76 | 0.130 |
Why?
|
| Estrogens, Non-Steroidal | 1 | 1995 | 54 | 0.130 |
Why?
|
| Quinoxalines | 1 | 2016 | 289 | 0.120 |
Why?
|
| Histone Deacetylase Inhibitors | 2 | 2017 | 789 | 0.120 |
Why?
|
| Oligopeptides | 1 | 2000 | 1188 | 0.120 |
Why?
|
| Tetrahydroisoquinolines | 6 | 2005 | 90 | 0.120 |
Why?
|
| Receptors, Androgen | 1 | 2020 | 1055 | 0.120 |
Why?
|
| HIV-2 | 1 | 1995 | 167 | 0.120 |
Why?
|
| Drug Delivery Systems | 3 | 2020 | 2217 | 0.120 |
Why?
|
| Polyenes | 1 | 1994 | 69 | 0.120 |
Why?
|
| Leukemia, Myeloid, Acute | 3 | 2016 | 3524 | 0.120 |
Why?
|
| Spermine | 1 | 2013 | 70 | 0.120 |
Why?
|
| Antiviral Agents | 3 | 1995 | 2984 | 0.120 |
Why?
|
| Anemia, Refractory, with Excess of Blasts | 1 | 2013 | 17 | 0.110 |
Why?
|
| Colorectal Neoplasms | 4 | 2013 | 6773 | 0.110 |
Why?
|
| Neoplasm Staging | 12 | 2020 | 11036 | 0.110 |
Why?
|
| Nitro Compounds | 1 | 2012 | 74 | 0.110 |
Why?
|
| Class I Phosphatidylinositol 3-Kinases | 1 | 2016 | 890 | 0.110 |
Why?
|
| Eukaryotic Initiation Factor-4F | 1 | 2012 | 41 | 0.110 |
Why?
|
| Deoxycytidine | 3 | 2006 | 826 | 0.110 |
Why?
|
| Oleanolic Acid | 1 | 2012 | 43 | 0.110 |
Why?
|
| Indoles | 2 | 2012 | 1841 | 0.100 |
Why?
|
| Flucytosine | 1 | 2011 | 32 | 0.100 |
Why?
|
| Amino Sugars | 1 | 2011 | 40 | 0.100 |
Why?
|
| Survival Rate | 11 | 2021 | 12786 | 0.100 |
Why?
|
| Protein Kinase Inhibitors | 5 | 2020 | 5532 | 0.100 |
Why?
|
| Cytosine Deaminase | 1 | 2011 | 68 | 0.100 |
Why?
|
| Thiobarbiturates | 1 | 1991 | 5 | 0.100 |
Why?
|
| Receptors, Notch | 1 | 2016 | 739 | 0.100 |
Why?
|
| Eukaryotic Initiation Factor-2 | 1 | 2012 | 190 | 0.100 |
Why?
|
| Carcinoma, Hepatocellular | 2 | 2013 | 2217 | 0.100 |
Why?
|
| Benzenesulfonates | 1 | 2011 | 169 | 0.100 |
Why?
|
| Galectin 1 | 1 | 2011 | 131 | 0.090 |
Why?
|
| Luteinizing Hormone | 2 | 2007 | 867 | 0.090 |
Why?
|
| eIF-2 Kinase | 1 | 2011 | 151 | 0.090 |
Why?
|
| Liver Neoplasms | 3 | 2013 | 4251 | 0.090 |
Why?
|
| Anti-HIV Agents | 2 | 2010 | 4255 | 0.090 |
Why?
|
| Drug Substitution | 1 | 2013 | 281 | 0.090 |
Why?
|
| Epothilones | 1 | 2010 | 44 | 0.090 |
Why?
|
| Neoplasm Proteins | 2 | 2021 | 3706 | 0.090 |
Why?
|
| HIV Fusion Inhibitors | 1 | 2010 | 81 | 0.090 |
Why?
|
| Hydrocarbons | 1 | 2010 | 105 | 0.090 |
Why?
|
| Time Factors | 14 | 2016 | 40038 | 0.090 |
Why?
|
| Topotecan | 4 | 2005 | 137 | 0.080 |
Why?
|
| Models, Chemical | 3 | 2007 | 626 | 0.080 |
Why?
|
| Urea | 1 | 2011 | 450 | 0.080 |
Why?
|
| Antifungal Agents | 1 | 1994 | 729 | 0.080 |
Why?
|
| Microbubbles | 2 | 2020 | 128 | 0.080 |
Why?
|
| Escherichia coli Proteins | 1 | 2015 | 1050 | 0.080 |
Why?
|
| Leukemia | 2 | 2013 | 1509 | 0.080 |
Why?
|
| Multiple Myeloma | 2 | 2017 | 5185 | 0.080 |
Why?
|
| Doxorubicin | 6 | 2014 | 2234 | 0.080 |
Why?
|
| Drug Screening Assays, Antitumor | 3 | 2021 | 729 | 0.080 |
Why?
|
| Animals | 23 | 2020 | 168660 | 0.080 |
Why?
|
| Melanoma, Experimental | 1 | 2011 | 560 | 0.080 |
Why?
|
| Follow-Up Studies | 10 | 2021 | 39001 | 0.080 |
Why?
|
| HSP90 Heat-Shock Proteins | 2 | 2021 | 434 | 0.080 |
Why?
|
| Remission Induction | 4 | 2016 | 2384 | 0.080 |
Why?
|
| Gene Expression Regulation, Neoplastic | 3 | 2016 | 8430 | 0.080 |
Why?
|
| Neoplastic Stem Cells | 1 | 2016 | 1376 | 0.080 |
Why?
|
| Quinolines | 1 | 2013 | 732 | 0.080 |
Why?
|
| Precursor B-Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2009 | 222 | 0.080 |
Why?
|
| Escherichia coli | 3 | 2015 | 4216 | 0.080 |
Why?
|
| Simplexvirus | 1 | 2011 | 803 | 0.080 |
Why?
|
| Biological Availability | 3 | 2010 | 397 | 0.080 |
Why?
|
| Naphthoquinones | 1 | 2008 | 77 | 0.080 |
Why?
|
| Xenograft Model Antitumor Assays | 5 | 2016 | 3547 | 0.080 |
Why?
|
| Mice | 18 | 2016 | 81154 | 0.080 |
Why?
|
| Phenytoin | 1 | 2008 | 197 | 0.070 |
Why?
|
| Cytarabine | 3 | 2016 | 692 | 0.070 |
Why?
|
| Liver Function Tests | 2 | 2013 | 529 | 0.070 |
Why?
|
| Mice, Inbred DBA | 2 | 2001 | 642 | 0.070 |
Why?
|
| Peptides | 3 | 2011 | 4406 | 0.070 |
Why?
|
| Salvage Therapy | 2 | 2003 | 1275 | 0.070 |
Why?
|
| Rats, Long-Evans | 1 | 2007 | 387 | 0.070 |
Why?
|
| Methotrexate | 2 | 2014 | 1726 | 0.070 |
Why?
|
| Mucin-1 | 1 | 2011 | 544 | 0.070 |
Why?
|
| Cystadenocarcinoma, Papillary | 1 | 2006 | 59 | 0.070 |
Why?
|
| Soy Milk | 1 | 2005 | 5 | 0.070 |
Why?
|
| Biotransformation | 2 | 2000 | 168 | 0.070 |
Why?
|
| Rats | 5 | 2020 | 24250 | 0.070 |
Why?
|
| Oncolytic Virotherapy | 1 | 2011 | 498 | 0.070 |
Why?
|
| Aged, 80 and over | 14 | 2021 | 57744 | 0.070 |
Why?
|
| Enzyme Induction | 1 | 2006 | 475 | 0.070 |
Why?
|
| Leucovorin | 2 | 2007 | 628 | 0.070 |
Why?
|
| Angiogenesis Inhibitors | 3 | 2009 | 2037 | 0.070 |
Why?
|
| Mice, Inbred BALB C | 4 | 2011 | 6380 | 0.070 |
Why?
|
| Mass Spectrometry | 4 | 2009 | 2203 | 0.070 |
Why?
|
| Receptors, Vascular Endothelial Growth Factor | 1 | 2009 | 664 | 0.060 |
Why?
|
| Cell Line, Tumor | 7 | 2021 | 16674 | 0.060 |
Why?
|
| Drug Hypersensitivity | 2 | 2013 | 884 | 0.060 |
Why?
|
| Thiazoles | 1 | 2012 | 1482 | 0.060 |
Why?
|
| Soft Tissue Neoplasms | 2 | 2005 | 1363 | 0.060 |
Why?
|
| TOR Serine-Threonine Kinases | 1 | 2014 | 2110 | 0.060 |
Why?
|
| Flavonoids | 2 | 2013 | 443 | 0.060 |
Why?
|
| Drug Interactions | 5 | 2009 | 1460 | 0.060 |
Why?
|
| Antineoplastic Agents, Hormonal | 1 | 2013 | 1523 | 0.060 |
Why?
|
| Survival Analysis | 6 | 2016 | 10251 | 0.060 |
Why?
|
| Alkyl and Aryl Transferases | 1 | 2004 | 89 | 0.060 |
Why?
|
| Infusions, Parenteral | 2 | 2019 | 419 | 0.060 |
Why?
|
| Mixed Tumor, Mullerian | 1 | 2003 | 56 | 0.060 |
Why?
|
| Neoplasm Invasiveness | 2 | 2016 | 3617 | 0.060 |
Why?
|
| Genes, erbB-1 | 1 | 2004 | 161 | 0.060 |
Why?
|
| Idarubicin | 2 | 2016 | 62 | 0.060 |
Why?
|
| Drug Resistance, Neoplasm | 5 | 2017 | 5170 | 0.060 |
Why?
|
| Injections, Intramuscular | 2 | 2015 | 553 | 0.060 |
Why?
|
| Staurosporine | 1 | 2004 | 251 | 0.060 |
Why?
|
| Nitriles | 2 | 2020 | 953 | 0.060 |
Why?
|
| Disease Progression | 6 | 2013 | 13273 | 0.050 |
Why?
|
| Prognosis | 7 | 2021 | 29052 | 0.050 |
Why?
|
| Polycystic Ovary Syndrome | 1 | 2007 | 370 | 0.050 |
Why?
|
| Oligonucleotides, Antisense | 1 | 2005 | 432 | 0.050 |
Why?
|
| Clinical Trials, Phase I as Topic | 2 | 2004 | 323 | 0.050 |
Why?
|
| Pyrroles | 1 | 2009 | 1147 | 0.050 |
Why?
|
| Tablets | 1 | 2022 | 145 | 0.050 |
Why?
|
| Reproducibility of Results | 7 | 2004 | 19894 | 0.050 |
Why?
|
| Breast Neoplasms | 3 | 2022 | 20827 | 0.050 |
Why?
|
| Depsipeptides | 1 | 2002 | 94 | 0.050 |
Why?
|
| Transaminases | 1 | 2002 | 200 | 0.050 |
Why?
|
| Complementary Therapies | 1 | 2005 | 485 | 0.050 |
Why?
|
| Urinary Bladder Neoplasms | 1 | 2014 | 2248 | 0.050 |
Why?
|
| Genistein | 2 | 2005 | 88 | 0.050 |
Why?
|
| Nuclear Proteins | 1 | 2016 | 5854 | 0.050 |
Why?
|
| Mice, Nude | 3 | 2012 | 3680 | 0.050 |
Why?
|
| Neovascularization, Pathologic | 2 | 2016 | 2638 | 0.050 |
Why?
|
| Central Nervous System Neoplasms | 1 | 2009 | 895 | 0.050 |
Why?
|
| HIV-1 | 2 | 1995 | 6939 | 0.050 |
Why?
|
| Niacinamide | 2 | 2013 | 416 | 0.040 |
Why?
|
| Astrocytoma | 1 | 2005 | 790 | 0.040 |
Why?
|
| Young Adult | 9 | 2021 | 56392 | 0.040 |
Why?
|
| Brain Edema | 2 | 2020 | 617 | 0.040 |
Why?
|
| Anti-Bacterial Agents | 1 | 1998 | 7172 | 0.040 |
Why?
|
| Magnetic Resonance Imaging | 6 | 2020 | 35409 | 0.040 |
Why?
|
| Pharmacogenetics | 1 | 2004 | 674 | 0.040 |
Why?
|
| Colonic Neoplasms | 1 | 2011 | 2542 | 0.040 |
Why?
|
| Pyridines | 1 | 2011 | 2827 | 0.040 |
Why?
|
| Antibodies, Monoclonal | 1 | 2016 | 9272 | 0.040 |
Why?
|
| Immunosuppressive Agents | 2 | 2012 | 4152 | 0.040 |
Why?
|
| Sequence Deletion | 1 | 2004 | 1524 | 0.040 |
Why?
|
| Purpura | 1 | 2020 | 122 | 0.040 |
Why?
|
| NF-kappa B | 2 | 2022 | 2500 | 0.040 |
Why?
|
| Phenols | 2 | 1995 | 496 | 0.040 |
Why?
|
| Adolescent | 12 | 2021 | 85729 | 0.040 |
Why?
|
| Phthalazines | 1 | 2021 | 359 | 0.040 |
Why?
|
| Phenylthiohydantoin | 1 | 2020 | 193 | 0.040 |
Why?
|
| Rats, Inbred F344 | 1 | 2020 | 862 | 0.040 |
Why?
|
| Proto-Oncogene Proteins c-akt | 2 | 2022 | 2504 | 0.040 |
Why?
|
| Leukocytes, Mononuclear | 1 | 2005 | 1836 | 0.040 |
Why?
|
| Drug Repositioning | 1 | 2021 | 230 | 0.040 |
Why?
|
| Melanoma | 3 | 2012 | 5508 | 0.040 |
Why?
|
| Gestational Age | 1 | 2007 | 3488 | 0.040 |
Why?
|
| Benzimidazoles | 1 | 2023 | 850 | 0.040 |
Why?
|
| HSP70 Heat-Shock Proteins | 1 | 2020 | 403 | 0.040 |
Why?
|
| Mullerian Ducts | 1 | 2019 | 198 | 0.040 |
Why?
|
| Chemotherapy, Adjuvant | 2 | 2019 | 3480 | 0.040 |
Why?
|
| Protein Binding | 3 | 2011 | 9377 | 0.040 |
Why?
|
| Sensitivity and Specificity | 3 | 1998 | 14714 | 0.040 |
Why?
|
| Kaplan-Meier Estimate | 3 | 2015 | 6539 | 0.040 |
Why?
|
| Half-Life | 2 | 1999 | 660 | 0.040 |
Why?
|
| Mibefradil | 1 | 2017 | 6 | 0.040 |
Why?
|
| Clinical Trials, Phase II as Topic | 1 | 2020 | 629 | 0.040 |
Why?
|
| Osteosarcoma | 1 | 2003 | 881 | 0.040 |
Why?
|
| Cyclin-Dependent Kinases | 1 | 2001 | 671 | 0.040 |
Why?
|
| Collagen | 2 | 2005 | 2681 | 0.040 |
Why?
|
| Child, Preschool | 6 | 2021 | 40964 | 0.040 |
Why?
|
| Gene Expression Regulation, Leukemic | 1 | 2021 | 651 | 0.040 |
Why?
|
| Swine | 1 | 2007 | 5909 | 0.040 |
Why?
|
| Neutropenia | 1 | 2002 | 895 | 0.040 |
Why?
|
| Reference Standards | 2 | 2002 | 1023 | 0.040 |
Why?
|
| Macrolides | 1 | 1998 | 201 | 0.040 |
Why?
|
| Aminopterin | 1 | 2016 | 15 | 0.040 |
Why?
|
| Adenocarcinoma | 2 | 2012 | 6363 | 0.040 |
Why?
|
| Combined Modality Therapy | 4 | 2014 | 8637 | 0.040 |
Why?
|
| Clinical Trials, Phase III as Topic | 1 | 2020 | 841 | 0.040 |
Why?
|
| Protein-Tyrosine Kinases | 2 | 2004 | 2453 | 0.040 |
Why?
|
| Recurrence | 4 | 2013 | 8337 | 0.040 |
Why?
|
| Ovariectomy | 1 | 2019 | 661 | 0.030 |
Why?
|
| Brain | 3 | 2019 | 26345 | 0.030 |
Why?
|
| Structure-Activity Relationship | 2 | 2010 | 3128 | 0.030 |
Why?
|
| Magnetic Resonance Spectroscopy | 2 | 2000 | 3758 | 0.030 |
Why?
|
| Transcription Factors | 1 | 2016 | 12209 | 0.030 |
Why?
|
| Drug Evaluation, Preclinical | 1 | 2001 | 1374 | 0.030 |
Why?
|
| Automation | 1 | 1998 | 584 | 0.030 |
Why?
|
| Leukocyte Count | 1 | 2000 | 1588 | 0.030 |
Why?
|
| Infant | 5 | 2021 | 35122 | 0.030 |
Why?
|
| Carcinosarcoma | 1 | 2016 | 108 | 0.030 |
Why?
|
| Tyrphostins | 1 | 1995 | 67 | 0.030 |
Why?
|
| Random Allocation | 1 | 2020 | 2429 | 0.030 |
Why?
|
| Clinical Trials as Topic | 3 | 2016 | 7908 | 0.030 |
Why?
|
| Gene Products, gag | 1 | 1995 | 337 | 0.030 |
Why?
|
| Tumor Cells, Cultured | 3 | 2005 | 6311 | 0.030 |
Why?
|
| Biological Transport | 1 | 2019 | 2119 | 0.030 |
Why?
|
| Child | 8 | 2021 | 77637 | 0.030 |
Why?
|
| Genes, myc | 1 | 2016 | 399 | 0.030 |
Why?
|
| Intention to Treat Analysis | 1 | 2015 | 426 | 0.030 |
Why?
|
| Benzoquinones | 1 | 1995 | 201 | 0.030 |
Why?
|
| Growth Inhibitors | 1 | 1995 | 385 | 0.030 |
Why?
|
| Uterine Neoplasms | 1 | 2003 | 1513 | 0.030 |
Why?
|
| Karnofsky Performance Status | 1 | 2013 | 173 | 0.030 |
Why?
|
| Disulfides | 1 | 1995 | 457 | 0.030 |
Why?
|
| Gastrointestinal Neoplasms | 1 | 2002 | 991 | 0.030 |
Why?
|
| Neoplasm Metastasis | 4 | 2007 | 4848 | 0.030 |
Why?
|
| Cyclopentanes | 1 | 1993 | 91 | 0.030 |
Why?
|
| Capsid | 1 | 1995 | 437 | 0.030 |
Why?
|
| Polymorphism, Genetic | 1 | 2004 | 4326 | 0.030 |
Why?
|
| Lactams, Macrocyclic | 1 | 1995 | 319 | 0.030 |
Why?
|
| NAD(P)H Dehydrogenase (Quinone) | 1 | 2012 | 46 | 0.030 |
Why?
|
| Indazoles | 1 | 2014 | 290 | 0.030 |
Why?
|
| Cystadenocarcinoma, Serous | 1 | 2016 | 450 | 0.030 |
Why?
|
| Capsid Proteins | 1 | 1995 | 479 | 0.030 |
Why?
|
| Cohort Studies | 5 | 2008 | 40545 | 0.030 |
Why?
|
| Karyotyping | 1 | 2014 | 1243 | 0.030 |
Why?
|
| Vincristine | 1 | 2014 | 1039 | 0.030 |
Why?
|
| Hydrazones | 1 | 2012 | 102 | 0.030 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p21 | 1 | 2013 | 365 | 0.030 |
Why?
|
| Mice, Inbred Strains | 1 | 1995 | 1826 | 0.030 |
Why?
|
| Proteasome Endopeptidase Complex | 2 | 2010 | 1335 | 0.030 |
Why?
|
| Lymphocyte Subsets | 1 | 2013 | 315 | 0.030 |
Why?
|
| Endothelial Cells | 1 | 2005 | 3482 | 0.030 |
Why?
|
| Esophageal Neoplasms | 1 | 2002 | 1585 | 0.030 |
Why?
|
| STAT Transcription Factors | 1 | 2012 | 182 | 0.020 |
Why?
|
| Cell Proliferation | 3 | 2012 | 10477 | 0.020 |
Why?
|
| HT29 Cells | 1 | 2011 | 200 | 0.020 |
Why?
|
| Head and Neck Neoplasms | 1 | 2005 | 2736 | 0.020 |
Why?
|
| Thalidomide | 1 | 2016 | 890 | 0.020 |
Why?
|
| Injections, Intravenous | 1 | 1993 | 1422 | 0.020 |
Why?
|
| Janus Kinases | 1 | 2012 | 244 | 0.020 |
Why?
|
| Follicle Stimulating Hormone | 2 | 2007 | 745 | 0.020 |
Why?
|
| Osteonecrosis | 1 | 2013 | 227 | 0.020 |
Why?
|
| Bone Neoplasms | 1 | 2003 | 2529 | 0.020 |
Why?
|
| Lymphocyte Count | 1 | 2013 | 793 | 0.020 |
Why?
|
| Yeasts | 1 | 2011 | 284 | 0.020 |
Why?
|
| Necrosis | 1 | 1995 | 1642 | 0.020 |
Why?
|
| Proto-Oncogene Proteins c-myc | 1 | 2016 | 988 | 0.020 |
Why?
|
| Anemia | 1 | 2000 | 1502 | 0.020 |
Why?
|
| Cyclin D1 | 1 | 2012 | 463 | 0.020 |
Why?
|
| Acetylglucosamine | 1 | 2011 | 191 | 0.020 |
Why?
|
| Canada | 1 | 2015 | 2064 | 0.020 |
Why?
|
| RNA, Messenger | 3 | 2012 | 13028 | 0.020 |
Why?
|
| Antibodies, Monoclonal, Murine-Derived | 1 | 2013 | 693 | 0.020 |
Why?
|
| Peptide Fragments | 1 | 2002 | 5096 | 0.020 |
Why?
|
| Postmenopause | 1 | 1999 | 2458 | 0.020 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2005 | 4033 | 0.020 |
Why?
|
| Radionuclide Imaging | 1 | 2014 | 2034 | 0.020 |
Why?
|
| Vascular Endothelial Growth Factor Receptor-1 | 1 | 2013 | 552 | 0.020 |
Why?
|
| Prednisone | 1 | 2014 | 1574 | 0.020 |
Why?
|
| Gene Expression Profiling | 2 | 2021 | 9440 | 0.020 |
Why?
|
| DNA Topoisomerases, Type I | 2 | 2002 | 102 | 0.020 |
Why?
|
| Liver | 3 | 2009 | 7479 | 0.020 |
Why?
|
| NF-E2-Related Factor 2 | 1 | 2012 | 379 | 0.020 |
Why?
|
| Demography | 1 | 2014 | 1653 | 0.020 |
Why?
|
| Body Mass Index | 1 | 2007 | 12718 | 0.020 |
Why?
|
| Rats, Sprague-Dawley | 1 | 2020 | 8300 | 0.020 |
Why?
|
| RNA Polymerase II | 1 | 2013 | 548 | 0.020 |
Why?
|
| Amino Acid Sequence | 3 | 2011 | 13809 | 0.020 |
Why?
|
| Microdialysis | 1 | 2008 | 158 | 0.020 |
Why?
|
| Immunophenotyping | 1 | 2013 | 1880 | 0.020 |
Why?
|
| Viral Proteins | 1 | 1995 | 1899 | 0.020 |
Why?
|
| Transgenes | 1 | 2011 | 1008 | 0.020 |
Why?
|
| Mutation | 4 | 2016 | 29777 | 0.020 |
Why?
|
| Acetylation | 1 | 1991 | 1084 | 0.020 |
Why?
|
| Antimetabolites, Antineoplastic | 1 | 2011 | 640 | 0.020 |
Why?
|
| Molecular Sequence Data | 3 | 2011 | 18107 | 0.020 |
Why?
|
| B-Lymphocytes | 1 | 2021 | 4665 | 0.020 |
Why?
|
| Insulin | 1 | 2022 | 6584 | 0.020 |
Why?
|
| Temperature | 1 | 1994 | 2202 | 0.020 |
Why?
|
| Neutrophils | 1 | 2000 | 3718 | 0.020 |
Why?
|
| Haplorhini | 1 | 2008 | 548 | 0.020 |
Why?
|
| Pilot Projects | 1 | 2020 | 8316 | 0.020 |
Why?
|
| Antibodies, Neutralizing | 1 | 2016 | 1978 | 0.020 |
Why?
|
| Chromatography, Liquid | 1 | 1991 | 975 | 0.020 |
Why?
|
| Endometrial Neoplasms | 1 | 2016 | 1350 | 0.020 |
Why?
|
| Hallucinations | 1 | 2009 | 358 | 0.020 |
Why?
|
| Ultrasonography | 1 | 2019 | 5986 | 0.020 |
Why?
|
| Proteins | 1 | 2001 | 6098 | 0.020 |
Why?
|
| Autophagy | 1 | 2014 | 1296 | 0.020 |
Why?
|
| Interleukin-10 | 1 | 2011 | 1200 | 0.020 |
Why?
|
| Lymphatic Metastasis | 1 | 2014 | 2924 | 0.020 |
Why?
|
| Contrast Media | 1 | 2019 | 5301 | 0.020 |
Why?
|
| Glucuronides | 1 | 2005 | 20 | 0.020 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 1 | 2013 | 1434 | 0.020 |
Why?
|
| Amifostine | 1 | 2005 | 41 | 0.020 |
Why?
|
| Estradiol | 2 | 2007 | 2017 | 0.020 |
Why?
|
| Pregnancy | 1 | 2007 | 29140 | 0.020 |
Why?
|
| Fallopian Tubes | 1 | 2006 | 182 | 0.020 |
Why?
|
| Phosphorothioate Oligonucleotides | 1 | 2005 | 10 | 0.020 |
Why?
|
| Cell Death | 1 | 2011 | 1705 | 0.020 |
Why?
|
| Skin Neoplasms | 1 | 2005 | 5691 | 0.020 |
Why?
|
| Monitoring, Physiologic | 1 | 2013 | 1738 | 0.020 |
Why?
|
| Recombinant Proteins | 2 | 2007 | 6620 | 0.020 |
Why?
|
| Protein Biosynthesis | 1 | 2012 | 2123 | 0.020 |
Why?
|
| Protein Kinase C-alpha | 1 | 2005 | 112 | 0.020 |
Why?
|
| Arthralgia | 1 | 2009 | 456 | 0.020 |
Why?
|
| T-Lymphocytes, Cytotoxic | 1 | 2011 | 1821 | 0.020 |
Why?
|
| Cell Cycle Proteins | 1 | 2016 | 3463 | 0.020 |
Why?
|
| Umbilical Veins | 1 | 2005 | 433 | 0.020 |
Why?
|
| Prostaglandin-Endoperoxide Synthases | 1 | 2005 | 329 | 0.010 |
Why?
|
| Virus Replication | 1 | 2011 | 2535 | 0.010 |
Why?
|
| Metalloendopeptidases | 1 | 2005 | 396 | 0.010 |
Why?
|
| Species Specificity | 1 | 2008 | 2480 | 0.010 |
Why?
|
| Reactive Oxygen Species | 1 | 2011 | 2077 | 0.010 |
Why?
|
| Laminin | 1 | 2005 | 419 | 0.010 |
Why?
|
| Age Factors | 2 | 2015 | 18355 | 0.010 |
Why?
|
| Interferon-gamma | 1 | 2011 | 3205 | 0.010 |
Why?
|
| Immunohistochemistry | 1 | 2016 | 11360 | 0.010 |
Why?
|
| Cyclooxygenase Inhibitors | 1 | 2005 | 371 | 0.010 |
Why?
|
| Cyclooxygenase 2 Inhibitors | 1 | 2005 | 320 | 0.010 |
Why?
|
| Sequence Analysis, DNA | 1 | 2014 | 4803 | 0.010 |
Why?
|
| Acute Disease | 1 | 2013 | 7150 | 0.010 |
Why?
|
| Cyclooxygenase 2 | 1 | 2005 | 612 | 0.010 |
Why?
|
| Cell Transformation, Neoplastic | 1 | 2012 | 2942 | 0.010 |
Why?
|
| Drug Stability | 1 | 2002 | 291 | 0.010 |
Why?
|
| Mitochondria | 1 | 1995 | 3513 | 0.010 |
Why?
|
| Endostatins | 1 | 2002 | 174 | 0.010 |
Why?
|
| Nausea | 1 | 2005 | 674 | 0.010 |
Why?
|
| Genetic Vectors | 1 | 2011 | 3421 | 0.010 |
Why?
|
| Prostatic Neoplasms | 1 | 2005 | 11059 | 0.010 |
Why?
|
| Drugs, Investigational | 1 | 2004 | 214 | 0.010 |
Why?
|
| HEK293 Cells | 1 | 2011 | 4204 | 0.010 |
Why?
|
| Proteoglycans | 1 | 2005 | 837 | 0.010 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2014 | 3591 | 0.010 |
Why?
|
| DNA Topoisomerases, Type II | 1 | 2002 | 121 | 0.010 |
Why?
|
| Medical Oncology | 1 | 2013 | 2267 | 0.010 |
Why?
|
| Epidermal Growth Factor | 1 | 2004 | 709 | 0.010 |
Why?
|
| Phosphatidylinositol 3-Kinases | 1 | 2011 | 2938 | 0.010 |
Why?
|
| Hematologic Diseases | 1 | 2005 | 498 | 0.010 |
Why?
|
| Phosphorylation | 1 | 2012 | 8436 | 0.010 |
Why?
|
| Proportional Hazards Models | 1 | 2015 | 12354 | 0.010 |
Why?
|
| Vascular Endothelial Growth Factors | 1 | 2002 | 771 | 0.010 |
Why?
|
| Fractures, Bone | 1 | 2013 | 1946 | 0.010 |
Why?
|
| Cell Survival | 1 | 2011 | 5881 | 0.010 |
Why?
|
| United States | 2 | 2021 | 69859 | 0.010 |
Why?
|
| Radiotherapy | 1 | 2008 | 1533 | 0.010 |
Why?
|
| Toxicity Tests | 1 | 2001 | 121 | 0.010 |
Why?
|
| Fibroblast Growth Factor 2 | 1 | 2002 | 599 | 0.010 |
Why?
|
| Radiotherapy, Adjuvant | 1 | 2005 | 1770 | 0.010 |
Why?
|
| Isoenzymes | 1 | 2005 | 1728 | 0.010 |
Why?
|
| Endothelial Growth Factors | 1 | 2002 | 693 | 0.010 |
Why?
|
| Protein Kinase C | 1 | 2005 | 1227 | 0.010 |
Why?
|
| Probability | 1 | 2005 | 2505 | 0.010 |
Why?
|
| Calibration | 1 | 2002 | 816 | 0.010 |
Why?
|
| Feasibility Studies | 1 | 2009 | 5078 | 0.010 |
Why?
|
| Quality Control | 1 | 2002 | 841 | 0.010 |
Why?
|
| Drug Combinations | 1 | 2005 | 1958 | 0.010 |
Why?
|
| Aspartate Aminotransferases | 1 | 2001 | 418 | 0.010 |
Why?
|
| Lymphokines | 1 | 2002 | 948 | 0.010 |
Why?
|
| Glycoprotein Hormones, alpha Subunit | 1 | 1999 | 98 | 0.010 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2008 | 3917 | 0.010 |
Why?
|
| RNA, Neoplasm | 1 | 2002 | 769 | 0.010 |
Why?
|
| Multivariate Analysis | 1 | 2013 | 12243 | 0.010 |
Why?
|
| Radiotherapy Dosage | 1 | 2005 | 2879 | 0.010 |
Why?
|
| Thyroid Neoplasms | 1 | 2012 | 2282 | 0.010 |
Why?
|
| Hormone Antagonists | 1 | 1999 | 108 | 0.010 |
Why?
|
| Receptors, LHRH | 1 | 1999 | 160 | 0.010 |
Why?
|
| Drug Therapy, Combination | 1 | 2009 | 6487 | 0.010 |
Why?
|
| Alanine Transaminase | 1 | 2001 | 593 | 0.010 |
Why?
|
| Confidence Intervals | 1 | 2004 | 2971 | 0.010 |
Why?
|
| Colloids | 1 | 1998 | 136 | 0.010 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2005 | 3874 | 0.010 |
Why?
|
| DNA Primers | 1 | 2002 | 2891 | 0.010 |
Why?
|
| Heterozygote | 1 | 2004 | 2803 | 0.010 |
Why?
|
| Safety | 1 | 2002 | 1184 | 0.010 |
Why?
|
| Carcinoma, Renal Cell | 1 | 2012 | 3142 | 0.010 |
Why?
|
| Creatinine | 1 | 2002 | 1918 | 0.010 |
Why?
|
| Chemistry, Pharmaceutical | 1 | 1998 | 277 | 0.010 |
Why?
|
| Dipeptides | 1 | 1999 | 409 | 0.010 |
Why?
|
| Granulocyte Colony-Stimulating Factor | 1 | 1999 | 648 | 0.010 |
Why?
|
| Rhodamine 123 | 1 | 1995 | 38 | 0.010 |
Why?
|
| Severity of Illness Index | 1 | 2013 | 15526 | 0.010 |
Why?
|
| Statistics, Nonparametric | 1 | 2001 | 2883 | 0.010 |
Why?
|
| Gastrointestinal Diseases | 1 | 2004 | 1171 | 0.010 |
Why?
|
| Kidney Neoplasms | 1 | 2012 | 4260 | 0.010 |
Why?
|
| DNA Mutational Analysis | 1 | 2004 | 4183 | 0.010 |
Why?
|
| Seizures | 1 | 2008 | 2850 | 0.010 |
Why?
|
| Rhodamines | 1 | 1995 | 182 | 0.010 |
Why?
|
| gag Gene Products, Human Immunodeficiency Virus | 1 | 1995 | 222 | 0.010 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2002 | 4749 | 0.010 |
Why?
|
| Intracellular Membranes | 1 | 1995 | 391 | 0.010 |
Why?
|
| Quality of Life | 1 | 2015 | 12788 | 0.010 |
Why?
|
| Antigens, Neoplasm | 1 | 2002 | 1988 | 0.010 |
Why?
|
| Mice, Inbred C57BL | 1 | 2011 | 21824 | 0.010 |
Why?
|
| Chromatography, Gas | 1 | 1993 | 156 | 0.010 |
Why?
|
| Permeability | 1 | 1995 | 738 | 0.010 |
Why?
|
| Genotype | 1 | 2007 | 12944 | 0.010 |
Why?
|
| Base Sequence | 1 | 2004 | 12798 | 0.010 |
Why?
|
| Drug Resistance, Microbial | 1 | 1995 | 860 | 0.010 |
Why?
|
| Electrons | 1 | 1993 | 268 | 0.010 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2002 | 3510 | 0.010 |
Why?
|
| Skin | 1 | 2005 | 4372 | 0.010 |
Why?
|
| Kinetics | 1 | 1999 | 6476 | 0.010 |
Why?
|
| Diagnosis, Differential | 1 | 2006 | 12954 | 0.010 |
Why?
|
| Adenosine Triphosphate | 1 | 1995 | 2029 | 0.010 |
Why?
|
| Risk Factors | 1 | 2015 | 72252 | 0.010 |
Why?
|
| Membrane Proteins | 1 | 2005 | 7880 | 0.000 |
Why?
|
| Signal Transduction | 1 | 2011 | 23398 | 0.000 |
Why?
|
| Cell Division | 1 | 1995 | 4568 | 0.000 |
Why?
|
| Lung | 1 | 2005 | 9858 | 0.000 |
Why?
|
| DNA-Binding Proteins | 1 | 2002 | 9648 | 0.000 |
Why?
|
| Retrospective Studies | 1 | 2012 | 77410 | 0.000 |
Why?
|
| Risk Assessment | 1 | 2005 | 23327 | 0.000 |
Why?
|
| HIV Infections | 1 | 2010 | 16715 | 0.000 |
Why?
|
| Boston | 1 | 1996 | 9310 | 0.000 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2006 | 20121 | 0.000 |
Why?
|
| Cell Line | 1 | 1995 | 15993 | 0.000 |
Why?
|
| Prospective Studies | 1 | 2002 | 53250 | 0.000 |
Why?
|